Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Pharvaris (9EN) Stock Price & Analysis

1 Followers

9EN Stock Chart & Stats

€30.10-€0.45(-2.43%)
At close: 5:30 PM GMT+1
€25€27.5€30€32.5Aug 12Sep 2Sep 8Oct 1Oct 16Nov 10
Day’s Range
EUR 29.80 - EUR 31.45
52-Week Range
EUR 19.20 - EUR 38.25
Previous Close
EUR 30.85
Volume
N/A
Average Volume (3M)
10
Market Cap
EUR 2.15B
Enterprise Value
EUR 1.99B
Total Cash (Recent Filing)
EUR 318.28M
Total Debt (Recent Filing)
EUR 673.73K
Price to Earnings (P/E)
―
Beta
0.59
Next Earnings
Apr 08, 2027 (Est.)
EPS Estimate
-0.73
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Phase 3 Efficacy

The strong Phase 3 prophylaxis result supports deucrictibant’s potential clinical differentiation in hereditary angioedema. Demonstrated efficacy across patient subgroups and sustained disease control could strengthen adoption prospects if regulatory review confirms the findings.

Regulatory Progress And Funding

Advancing U.S. and European regulatory reviews reduce development uncertainty while the strengthened cash position supports continued trials and pre-commercial preparation. A runway extending into 2028 gives Pharvaris time to pursue approvals without immediate dependence on additional financing.

Low Financial Leverage

Extremely low debt limits interest and refinancing pressure, preserving financial flexibility during the company’s development phase. The sizable equity base provides capacity to fund research, regulatory work, and potential commercialization while avoiding the constraints associated with heavy leverage.

Bears Say

Pre-Revenue Business

Pharvaris has not yet generated product revenue, so its business model remains dependent on clinical success and eventual regulatory approval. Until commercialization begins, the company lacks an operating revenue base to offset research, development, and launch-related spending.

Persistent Cash Burn

The scale and persistence of cash outflows indicate that Pharvaris consumes substantial capital to fund operations and clinical programs. Continued negative free cash flow can require future financing, creating dilution or funding pressure if commercialization takes longer than expected.

Widening Losses

Deepening net losses and consistently negative returns on equity show that spending has not yet translated into improving profitability. This weak earnings trajectory may persist through development and regulatory preparation, limiting internal capital generation and shareholder returns.

Pharvaris News

9EN FAQ

What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was €19.20 and its highest was €38.25 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is €2.15B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s next earnings report is estimated for Apr 08, 2027 (not yet confirmed), which is in 146 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Nov 12, 2026. The company reported -€0.67 earnings per share for the quarter, beating the consensus estimate of -€0.718 by €0.048.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate is -0.73.
How many shares outstanding does Pharvaris have?
Pharvaris has 70,204,506 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -€0.67 in its last earnings report, beating expectations of -€0.718. Following the earnings report the stock price went up 4.69%.
Which hedge fund is a major shareholder of Pharvaris?
Hedge funds hold Pharvaris shares: the largest hedge-fund position in Pharvaris is 1,567,101,222 shares, and hedge funds decreased their holdings by 81.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology